Company Overview and News

KLCI holds position above 1,800 level, gains seen capped

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719

Bursa rebounds to open higher

2018-08-07 malaymail
KUALA LUMPUR, Aug 7 — Bursa Malaysia rebounded from yesterday's losses to open higher today, taking cue from the overnight performance of Wall Street and amid rising crude oil prices.
0143 7172 PNADF PBLOF 1295 BSMAF PNAGF 6033 1818

KLCI rises 0.29% as select blue chips lift

2018-08-07 theedgemarkets - 1
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.29% in early trade this morning, tracking the steady regional markets, lifted by select index-linked blue chips.
HLFBF 7172 1082 BATS 4162 5246 3034 6033 KLKBY 2445 PNADF 5819 PNAGF 3719

KLCI claws into positive territory as Tenaga lifts

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF

KLCI pares loss as foreign selling slows down

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI pared some of its losses at midday break today, despite weaker regional markets, as foreign selling of local equities remained measured for the fourth week running.
HLFBF 7172 UPBMF 1082 BATS 4162 7006 2089 7055 LIIHF KLKBY 5238 2445 4588 3867 5738 0026

KLCI dips 0.24% in line with regional markets

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI dipped 0.24% at mid-morning today, tracking regional losses, weighed by select index-linked blue chips.
7172 UPBMF 7006 2089 5014 9334 6033 5101 LIIHF 7123 KLKBY 5238 2445 4588 PNADF 5738 7216 0026 MYPRY 2836 PNAGF

Bursa snaps nine-day winning streak to end lower

2018-07-20 malaymail
KUALA LUMPUR, July 20 — Bursa Malaysia snapped a nine-day winning streak to close easier today on technical correction, amid a recovery in the Chinese market and overnight Wall Street decline, said a dealer.
7172 PBLOF 1589 1295 BSMAF 1818

Bursa Malaysia closes higher for eighth straight day

2018-07-18 malaymail
KUALA LUMPUR, July 18 — Bursa Malaysia closed higher for the eighth straight day today with gains seen across-the-board, save for the mining counter, as the Federal Reserve (Fed) Chair’s testimony last night had a positive spillover throughout markets, said a dealer.
0143 7172 PBLOF 1295 BSMAF 1818

KLCI reverses loss, rises 0.31% in line with region

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI reversed its earlier losses and rose 0.31% at midday break, tracking gains at most Asian markets.
HLFBF 7172 PBLOF 7053 1082 7087 1295 9334 7123 0143 4863 0156 8613 0026 6888 5819 AXXTF MYTEF 2836

KLCI pares down loss, tracks advance at key Asian markets

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI pared down its earlier losses substantially at mid-morning today, tracking the advance at key Asian markets.
7172 PBLOF 7053 8133 7087 1295 7153 7123 7079 0176 4588 3026 6645 5819

KLCI rises 1.38% on 1H18 window dressing, led by Tenaga

2018-06-29 theedgemarkets
KUALA LUMPUR (June 29): The FBM KLCI rose 1.38% at mid-morning today on 1H18 window-dressing activities, led by gains in Tenaga Nasional Bhd.
7172 7251 SPMXF 8621 7113 TPGVF 7765 5168 1481 5255 TGLVY 5139 KLKBY 2445 5216 SPMXY 5347 3026 0900 TNABY TNABF 1929 HRGHY

KLCI pares losses on feeble window-dressing activity

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI pared some of its losses at the midday break today amid some feeble window-dressing activities ahead of the final trading day of the first half of 2018 tomorrow.
HLFBF 7172 7052 PBLOF 7251 MLYNF 7113 BATS TPGVF 4162 1295 2089 9334 5347 3867 TNABY 2836 PNAGF MLYBY UPBMF 1082 2291 6033 TGLVY 1155 PNADF TNABF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...